Dergiler / Turkish Journal of Medical Sciences / 2020 / Cilt: 50 - Sayı: 8

Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata

Sayfa
1817–1824
Yayın Tarihi
2022-11-06
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

There was no statistically significant relation with other parameters, such as disease duration, age, sex, atopy history, age of onset, and histopathological features.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: Alopecia areata (AA) is an inflammatory disease with a genetic and autoimmune basis.
📊
Temel Bulgular & Veri:Materials and methods: In this retrospective study, 98 patients (60 males, 38 females) with alopecia, who were referred to the Hair Disease Polyclinic at the Department of Dermatology, between 2011 and 2015, were included.
💡
Sonuç & Katkı:There was no statistically significant relation with other parameters, such as disease duration, age, sex, atopy history, age of onset, and histopathological features.
🔬Tür:Araştırma Makalesi
📍Kapsam:2011 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: Alopecia areata (AA) is an inflammatory disease with a genetic and autoimmune basis. Herein, it was aimed to study the efficacy and safety of an immunomodulatory therapeutic agent, diphenylcyclopropenone, while manifesting its association with histopathological features, prognostic factors, and side effects. Materials and methods: In this retrospective study, 98 patients (60 males, 38 females) with alopecia, who were referred to the Hair Disease Polyclinic at the Department of Dermatology, between 2011 and 2015, were included. Together with medical histories and dermatological examinations, a skin biopsy for histopathological examination was conducted for all of the patients prior to therapy. Therapeutic success was evaluated on the basis of the hair regrowth percentage. Results: Regarding the overall treatment success, 33 (34%) patients had complete response, 16 (16%) had partial response (between 50% and 99%), 27 (28%) had minimal response (between 1% and 49%), and 22 (22%) were nonresponders. Both sexs were equally represented in the outcome. Conclusions: There was a significant relation between the severity of alopecia and the treatment outcome (P = 0.038). Patients with AA had significantly better response when compared to those with alopecia totalis and universalis. There was no statistically significant relation with other parameters, such as disease duration, age, sex, atopy history, age of onset, and histopathological features.

🔖

Bu Makaleye Atıf Yap

KUTLUBAY, Z., SERDAROĞLU, S., KEÇİCİ, A. S., VEHİD, S., AYDIN, Ö. (2022). Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 8, 1817–1824. https://ajindex.com/articles/609649

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. Journal of American Academy of Dermatology 2018; 78(1):1-12. doi:10.1016/j. jaad.2017.04.1141 2. Magen E, Chikovani T, Waitman DA, Kahan NR. Association of alopecia areata with atopic dermatitis and chronic spontaneous urticaria. Allergy Asthma Proceedings 2018; 39 (2): 96-102. doi:10.2500/aap.2018.39.4114 3. Happle R, Hausen BM, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Dermatology and Venereology 1983; 63 (2): 49-52. 4. Ito T, Aoshima M, Ito N, Uchiyama I, Sakamoto K et al. Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata. Archieves of Dermatological Research 2009; 301 (5): 373-80. doi:10.1007/s00403-009-0936-8 5. Rallis E, Nasiopoulou A, Kouskoukis C, Roussaki-Schulze A, Koumantaki E et al. Oral administration of cyclosporin A in patients with severe alopecia areata. International Journal of Tissue Reactions 2005; 27 (3): 107-110. doi:10.1016/S1578- 2190(09)70063-0 6. Smith JR, Akin RS, Wells MJ. Alopecia areata treated with efalizumab: a case with significant hair re-growth after longterm therapy. Journal of Drugs in Dermatology 2009; 8 (8): 758- 760. 7. Strober BE, Siu K, Alexis AF, Kim G, Washenik K et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. Journal of American Academy of Dermatology 2005; 52 (6): 1082-1084. doi:10.1016/j.jaad.2005.03.039 8. D’Ovidio R. Alopecia areata: news of diagnosis, pathogenesis, and treatment. Italian Journal of Dermatology and Venereology 2014; 149 (1): 25-45. doi:10.4103/ijt.ijt_99_17 9. Holzer AM, Kaplan LL, Lewis WR. Haptens as drugs: contact allergens are powerful topical immunomodulators. Journal of Drugs in Dermatology 2006; 5 (5): 410-416. 10. Wilkerson MG, Connor TH, Henkin J, Wilkin JK, Matney TS. Assessment of diphenylcyclopropenone for photochemically induced mutagenicity in the Ames assay. Journal of American Academy of Dermatology 1987; 17 (4): 606-611. doi:10.1016/ S0190-9622(87)70244-8 11. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part II. Treatment. Journal of American Academy of Dermatology 2010; 62 (2): 203-204. doi:10.1016/j. jaad.2009.10.031 12. Breslow R, Haynie R, Mirra J. The synthesis of diphenylcyclopropenone. Journal of the American Chemical Society 1959; 81 (3): 247-24